Display options
Cite
Wilkie GL, Qureshi WT, O'Day KW, et al. Cardiac and Obstetric Outcomes Associated With Mitral Valve Prolapse. Am J Cardiol. 2021;162:150-155doi: 10.1016/j.amjcard.2021.09.014.
Wilkie, G. L., Qureshi, W. T., O'Day, K. W., Aurigemma, G. P., Goldberg, R. J., Amjad, W., Alqalyoobi, S., Kakouros, N., Lauring, J. R., Leftwich, H. K., & Harrington, C. M. (2022). Cardiac and Obstetric Outcomes Associated With Mitral Valve Prolapse. The American journal of cardiology, 162150-155. https://doi.org/10.1016/j.amjcard.2021.09.014
Wilkie, Gianna L, et al. "Cardiac and Obstetric Outcomes Associated With Mitral Valve Prolapse." The American journal of cardiology vol. 162 (2022): 150-155. doi: https://doi.org/10.1016/j.amjcard.2021.09.014
Wilkie GL, Qureshi WT, O'Day KW, Aurigemma GP, Goldberg RJ, Amjad W, Alqalyoobi S, Kakouros N, Lauring JR, Leftwich HK, Harrington CM. Cardiac and Obstetric Outcomes Associated With Mitral Valve Prolapse. Am J Cardiol. 2022 Jan 01;162:150-155. doi: 10.1016/j.amjcard.2021.09.014. Epub 2021 Oct 22. PMID: 34689956.
Copy Download .nbib Format: NLM
Share it on

Am J Cardiol. 2022 Jan 01;162:150-155. doi: 10.1016/j.amjcard.2021.09.014. Epub 2021 Oct 22.

Cardiac and Obstetric Outcomes Associated With Mitral Valve Prolapse.

The American journal of cardiology

Gianna L Wilkie, Waqas T Qureshi, Kevin W O'Day, Gerard P Aurigemma, Robert J Goldberg, Waseem Amjad, Shehabaldin Alqalyoobi, Nikolaos Kakouros, Julianne R Lauring, Heidi K Leftwich, Colleen M Harrington

Affiliations

  1. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Massachusetts Memorial Healthcare.
  2. Division of Cardiovascular Medicine, University of Massachusetts Memorial Healthcare.
  3. Division of Cardiovascular Medicine, University of Massachusetts Memorial Healthcare; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts.
  4. Department of Internal Medicine, Albany Medical College, Albany, New York.
  5. Department of Pulmonary and Critical Care Medicine, East Carolina University, Greenville, North Carolina; Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, Kentucky.
  6. Division of Cardiovascular Medicine, University of Massachusetts Memorial Healthcare. Electronic address: [email protected].

PMID: 34689956 DOI: 10.1016/j.amjcard.2021.09.014

Abstract

Mitral valve prolapse (MVP) is the most common valvular heart disease in women of reproductive age. Whether MVP increases the likelihood of adverse outcomes in pregnancy is unknown. The study objective was to examine the cardiac and obstetric outcomes associated with MVP in pregnant women. This retrospective cohort study, using the Healthcare Cost and Utilization Project National Readmission Sample database between 2010 and 2017, identified all pregnant women with MVP using the International Classification of Disease, Ninth and Tenth Revisions codes. The maternal cardiac and obstetric outcomes in pregnant women diagnosed with MVP were compared with women without MVP using multivariable logistic and Cox proportional hazard regression models adjusted for baseline demographic characteristics. There were 23,000 pregnancy admissions with MVP with an overall incidence of 16.9 cases per 10,000 pregnancy admissions. Pregnant women with MVP were more likely to die during pregnancy (adjusted hazard ratio 5.13, 95% confidence interval [CI] 1.09 to 24.16), develop cardiac arrest (adjusted odds ratio [aOR] 4.44, 95% CI 1.04 to 18.89), arrhythmia (aOR 10.96, 95% CI 9.17 to 13.12), stroke (aOR 6.90, 95% CI 1.26 to 37.58), heart failure (aOR 5.81, 95% CI 3.84 to 8.79), or suffer a coronary artery dissection (aOR 25.22, 95% CI 3.42 to 186.07) compared with women without MVP. Pregnancies with MVP were also associated with increased risks of preterm delivery (aOR 1.21, 95% CI 1.02 to 1.44) and preeclampsia/hemolysis, elevated liver enzymes, and low platelets syndrome (aOR 1.22, 95% CI 1.05 to 1.41). In conclusion, MVP in pregnancy is associated with adverse maternal cardiac outcomes and higher obstetric risks.

Copyright © 2021 Elsevier Inc. All rights reserved.

Conflict of interest statement

Disclosures The authors have no conflicts of interest to declare.

Publication Types